Retatrutide
An investigational triple receptor agonist in human trials that is not an authorized Canadian drug product.
Status checked August 2, 2026The evidence desk
Topic: Clinical Trials
Source-led reporting and practical explainers from PeptideInfo.ca.
Peptides in Canada in 2026: What Is Authorized, What Is Experimental and What Health Canada Is Warning About
Health Canada issued a major warning about unauthorized injectable peptide drugs in 2026. Here is how Canadian authorization works, what current notices say, and why established medicines, clinical trials, and experimental products cannot be treated as one category.
Status checked August 2, 2026